Financial Ratios

MPS PHARMAA LTD.

NSE : NABSE : 531686ISIN CODE : INE537C01019Industry : Pharmaceuticals & DrugsHouse : Private
BSE3.000 (0 %)
PREV CLOSE ( ) 3.00
OPEN PRICE ( ) 3.05
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 25014
TODAY'S LOW / HIGH ( )2.87 3.17
52 WK LOW / HIGH ( ) 2.754.33
NSE
This Company is not listed in NSE
Select year
ParticularsMar2024Mar2023Mar2022Mar2021Mar2020
Operational & Financial Ratios
   Earnings Per Share (Rs)-0.43-0.55-0.07-2.31-0.61
   CEPS(Rs)-0.36-0.470.19-2.02-0.31
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)1.031.462.002.074.38
   Tax Rate(%)2.611.9284.821.735.63
Margin Ratios
   Core EBITDA Margin(%)-2079.400.00
   EBIT Margin(%)-2868.330.00
   Pre Tax Margin(%)-2880.220.00
   PAT Margin (%)-437.310.00
   Cash Profit Margin (%)1149.130.00
Performance Ratios
   ROA(%)-8.26-10.33-1.32-31.87-6.87
   ROE(%)-34.92-31.75-3.64-71.73-13.04
   ROCE(%)-9.06-11.15-9.64-36.90-8.08
   Asset Turnover(x)0.000.000.000.000.00
   Sales/Fixed Asset(x)0.000.000.000.000.00
   Working Capital/Sales(x)0.000.00-0.010.000.00
Efficiency Ratios
   Fixed Capital/Sales(x)485.453690.35
   Receivable days3546.470.00
   Inventory Days6293.930.00
   Payable days1303.80769.800.000.00
Valuation Parameters
   PER(x)0.000.000.000.000.00
   PCE(x)-8.96-4.447.14-0.37-1.16
   Price/Book(x)3.121.440.690.360.08
   Yield(%)0.000.000.000.000.00
   EV/Net Sales(x)261.011610.07
   EV/Core EBITDA(x)-19.02-11.66-20.36-1.80-10.61
   EV/EBIT(x)-15.74-10.07-9.10-1.58-5.69
   EV/CE(x)1.451.130.830.630.43
   M Cap / Sales82.05157.64
Growth Ratio
   Net Sales Growth(%)-100.00-100.00-99.47
   Core EBITDA Growth(%)23.74-122.6689.45-493.925.58
   EBIT Growth(%)20.42-15.2179.32-263.634.23
   PAT Growth(%)20.88-641.9096.79-278.506.36
   EPS Growth(%)20.88-641.7296.79-278.466.35
Financial Stability Ratios
   Total Debt/Equity(x)3.692.421.521.440.76
   Current Ratio(x)0.270.290.330.330.71
   Quick Ratio(x)0.210.220.240.240.63
   Interest Cover(x)-448.07-990.70-241.16-1520.41-881.13
   Total Debt/Mcap(x)1.191.692.193.969.23

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.